Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Newsletter Article
|
Clinical Trial: SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution in Acute HFUS Fed News Service, Including US State News, 2024Copyright HT Digital Streams Limited Jun 4, 2024Digital Resources/Online E-Resources |
|
2 |
Material Type: Newsletter Article
|
The Christ Hospital Health Network Implants First-of-Its-Kind Device to Repair Leaky Heart ValveNews Bites - Private Companies, 2024Copyright News Bites Pty Ltd Jun 4, 2024Digital Resources/Online E-Resources |
|
3 |
Material Type: Newsletter Article
|
TELA Bio Appoints Jeffrey Blizard to its Board of DirectorsNASDAQ OMX's News Release Distribution Channel, 2024GlobeNewswire, Inc.Digital Resources/Online E-Resources |
|
4 |
Material Type: Newsletter Article
|
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ OMX's News Release Distribution Channel, 2024GlobeNewswire, Inc.Digital Resources/Online E-Resources |
|
5 |
Material Type: Newsletter Article
|
Ventricular Assist Device (VAD) Market Expected to Reach USD 3.08 Bn by 2032Financial Services Monitor Worldwide, 20242022 Global Data Point. All Rights Reserved. Provided by SyndiGate Media Inc. (Syndigate.info).Digital Resources/Online E-Resources |
|
6 |
Material Type: Newsletter Article
|
AstraZeneca: Tagrisso Reduced the Risk of Disease Progression or Death by 84% in Patients With Unresectable, Stage III EGFR-Mutated Lung Cancer vs. Placebo in LAURA Phase III TrialTargeted News Service, 2024Targeted News ServiceDigital Resources/Online E-Resources |
|
7 |
Material Type: Newsletter Article
|
Journal of the American College of Cardiology Issues Research Articles in June 11, 2024 EditionTargeted News Service, 2024Targeted News ServiceDigital Resources/Online E-Resources |
|
8 |
Material Type: Newsletter Article
|
AstraZeneca (AZN: GBX12,418.0) increases GBX72.0, lifts 3.2% for week; +GBX72 [0.6%] Vol Index 2.3 [1 is avg]Company Data Report, 2024Copyright News Bites Pty Ltd Jun 4, 2024Digital Resources/Online E-Resources |
|
9 |
Material Type: Newsletter Article
|
AstraZeneca (AZN: GBX12,418.0) strengthens above moving average price; +GBX72 [0.6%] Vol Index 2.3 [1 is avg]Company Data Report, 2024Copyright News Bites Pty Ltd Jun 4, 2024Digital Resources/Online E-Resources |
|
10 |
Material Type: Newsletter Article
|
INTERNATIONAL PATENT: THE CHILDREN'S MEDICAL CENTER CORPORATION FILES APPLICATION FOR "METHODS OF TREATING HEART FAILURE"US Fed News Service, Including US State News, 2024Copyright HT Digital Streams Limited Jun 4, 2024Digital Resources/Online E-Resources |
|
11 |
Material Type: Newsletter Article
|
AstraZeneca (AZN: GBX12,420.0) strengthens above moving average price; +GBX74 [0.6%]Company Data Report, 2024Copyright News Bites Pty Ltd Jun 4, 2024Digital Resources/Online E-Resources |
|
12 |
Material Type: Newsletter Article
|
AstraZeneca (AZN: GBX12,396.0) in 4th consecutive rise; +GBX50 [0.4%]Company Data Report, 2024Copyright News Bites Pty Ltd Jun 4, 2024Digital Resources/Online E-Resources |
|
13 |
Material Type: Newsletter Article
|
AstraZeneca (AZN: GBX12,420.0) lifts 0.6% against the trend; +GBX74 [0.6%]Company Data Report, 2024Copyright News Bites Pty Ltd Jun 4, 2024Digital Resources/Online E-Resources |
|
14 |
Material Type: Newsletter Article
|
AstraZeneca (AZN: GBX12,396.0) increases GBX50.0, lifts 3.1% for week; +GBX50 [0.4%]Company Data Report, 2024Copyright News Bites Pty Ltd Jun 4, 2024Digital Resources/Online E-Resources |
|
15 |
Material Type: Newsletter Article
|
Ventricular Assist Device (VAD) Market Expected to Reach USD 3.08 Bn by 2032: The global ventricular assist device (VAD) market is calculated at USD 1.66 billion in 2024 and is expected to reach around USD 3.08 billion by 2032, growing at a solid CAGR of 7.1% from 2024 to 2032NASDAQ OMX's News Release Distribution Channel, 2024GlobeNewswire, Inc.Digital Resources/Online E-Resources |
|
16 |
Material Type: Newsletter Article
|
AstraZeneca (AZN: GBX12,210.0) strengthens above moving average price; +GBX20 [0.2%] Vol Index 1.8 [1 is avg]Company Data Report, 2024Copyright News Bites Pty Ltd Jun 3, 2024Digital Resources/Online E-Resources |
|
17 |
Material Type: Newsletter Article
|
Monthly: Lexicon Pharmaceuticals (LXRX: $1.70) gains 10%, beating 87% of stocksNews Bites US - NASDAQ, 2024Copyright News Bites Pty Ltd Jun 3, 2024Digital Resources/Online E-Resources |
|
18 |
Material Type: Newsletter Article
|
Weekly: Lexicon Pharmaceuticals (LXRX: $1.70) climbs 6% on weak volume; +8c [4.9%]News Bites US - NASDAQ, 2024Copyright News Bites Pty Ltd Jun 3, 2024Digital Resources/Online E-Resources |
|
19 |
Material Type: Newsletter Article
|
Monthly: SeaStar Medical Holding (ICU: 37.14c) falls a second month, trailing 82% of stocksNews Bites US - NASDAQ, 2024Copyright News Bites Pty Ltd Jun 3, 2024Digital Resources/Online E-Resources |
|
20 |
Material Type: Newsletter Article
|
European Journal of Cardiovascular Nursing Issues Research Articles in May 2024 EditionTargeted News Service, 2024Targeted News ServiceDigital Resources/Online E-Resources |